Off the Beaten ASCO21 Track Part 1
There’s always a lot of time and attention focused around phase 3 clinical trial readouts at ASCO, but what about some of the hidden gems where we can learn quite a bit from earlier developments?
This is a two-part series this week where we go off the beaten track on the road less travelled to explore some novel approaches, which may or may not make an impact.
Don’t forget we can often learn as much from negative studies as we do from positive ones because they can teach us what not to do in terms of future design of anti-cancer therapies.
New product development is very much a process of Kaizen, or continuous improvement where we adapt both from what went less well as well as what worked really well.
This year’s ASCO data drop has some important lessons embedded within for those intrigued to dig deeper and pay attention to the finer details…
To learn more about our pre-ASCO meeting analysis to can get a heads up on key oncology commentary and insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
This content is restricted to subscribers
Fans of Harry Potter, will no doubt be familiar with the Goblet of Fire (“La Coupe de Feu” in the French version) and how it was used to select the champions from three schools of magic who would compete against each other in a tournament.
In other words, we need more firepower and novel rational combination approaches to stimulating both the innate and the adaptive immune systems in order to derive a more potent and durable response in a larger number of patients. That’s where TLR agonists come in.